N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-[4-(dimethylamino)piperidin-1-yl]-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | 1108743-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-[4-(dimethylamino)piperidin-1-yl]-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
• 英文别名: N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-(dimethylamino)piperidin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide；N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-[4-(dimethylamino)piperidin-1-yl]-2-(oxan-4-ylamino)benzamide
• CAS: 1108743-77-6
• 化学式: C₃₃H₃₈F₂N₆O₂
• 分子量: 588.701
• InChiKey: WJYASLCTLYUHOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  85.5
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'INDAZOLE SUBSTITUÉS ACTIFS COMME INHIBITEURS DE KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2009013126A1

  公开（公告）日：2009-01-29

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  公开了公式（I）的吲唑衍生物及其药用盐，如规范中定义的，以及它们的制备方法和包含它们的药物组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。
• Molecules for administration to ROS1 mutant cancer cells
  申请人：Ignyta, Inc.

  公开号：US10231965B2

  公开（公告）日：2019-03-19

  Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  公开了公式（I）或公式2的取代吲唑衍生物以及其药用盐，如规范中所定义，其制备方法和包含它们的药物组合物；该发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症方面有用。
• SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：LOMBARDI BORGIA Andrea

  公开号：US20130018036A1

  公开（公告）日：2013-01-17

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  本发明披露了式（I）的取代吲唑衍生物及其药学上可接受的盐，其定义在说明书中，以及其制备过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。
• N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO) BENZAMIDE FOR TREATING PATIENTS WITH ROS1,NTRK1, NTRK2 AND NTRK3 MUTANT CANCER CELLS
  申请人：Ignyta, Inc.

  公开号：EP3834827A1

  公开（公告）日：2021-06-16

  Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  本发明公开了式(I)或式2.(I)的取代吲唑衍生物及其药学上可接受的盐类（如说明书中所定义）、其制备工艺和包含它们的药物组合物；本发明的化合物可用于治疗与蛋白激酶活性失调有关的疾病（如癌症）。
• Substituted indazole derivatives active as kinase inhibitors
  申请人：NERVIANO MEDICAL SCIENCES S.R.L.

  公开号：US10081622B2

  公开（公告）日：2018-09-25

  Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

  如说明书中所定义的式(I)的取代吲唑衍生物及其药学上可接受的盐；本发明的化合物可用于治疗与蛋白激酶活性失调有关的疾病，如癌症。